2.80
-0.05(-1.75%)
Currency In USD
| Previous Close | 2.85 |
| Open | 2.88 |
| Day High | 2.94 |
| Day Low | 2.75 |
| 52-Week High | 3.67 |
| 52-Week Low | 0.99 |
| Volume | 3.04M |
| Average Volume | 2.87M |
| Market Cap | 269.54M |
| PE | -1.17 |
| EPS | -2.4 |
| Moving Average 50 Days | 2.43 |
| Moving Average 200 Days | 2.08 |
| Change | -0.05 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $280 as of February 17, 2026 at a share price of $2.8. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $238.1 as of February 17, 2026 at a share price of $2.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio Announces 2026 Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automate
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim